Coxeter

Coxeter is a biotechnology company specializing in the development of novel radiopharmaceuticals and radiochemistry technologies. Spun out from the University of Oxford, the company focuses on innovative methods for labeling molecules with fluorine-18 for use in Positron Emission Tomography (PET) imaging. Its proprietary technology aims to simplify and improve the production of PET tracers, particularly for oncology and neurology applications. Coxeter was acquired by Blue Earth Diagnostics in 2017 to bolster their molecular imaging pipeline and internal research capabilities. The company's work remains foundational to the development of next-generation PET imaging agents.